Omnitrope's Off-Label Future

The new copycat growth hormone from Novartis hasn't been approved for anti-aging. That won't stop buyers seeking a cheaper fountain of youth

When Sarah Sellers heard on May 31 that the U.S. Food & Drug Administration had approved a generic-like version of human growth hormone (HGH), she was less than thrilled. The product, called Omnitrope and made by a unit of Novartis (NVS), is the first low-cost, copycat biotech drug to be approved by the FDA.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.